Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 13/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22396074 | 0.84 | NEK2 (0.51) | LIPETSHRUSP2ALDH1A1CYP1A2 | |
| SCHEMBL745437 | 0.82 | LIPE (0.70) | LIPETSHR | |
| SCHEMBL744130 | 0.81 | LIPE (0.77) | LIPE | |
| SCHEMBL745784 | 0.81 | LIPE (0.53) | LIPETSHRUSP2ALDH1A1CYP1A2 | |
| SCHEMBL13075173 | 0.79 | LIPE (0.49) | LIPETSHRUSP2ALDH1A1CYP1A2 | |
| SCHEMBL748276 | 0.79 | LIPE (0.59) | LIPE | |
| SCHEMBL746188 | 0.78 | LIPE (0.60) | LIPE | |
| SCHEMBL746697 | 0.78 | LIPE (0.50) | LIPETSHRUSP2ALDH1A1CYP1A2 | |
| SCHEMBL744394 | 0.77 | ALDH1A1 (0.44) | LIPETSHRUSP2ALDH1A1CYP1A2 | |
| SCHEMBL3753670 | 0.77 | LIPE (0.75) | LIPEHSD11B1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233484-A1 | USE OF VITAMIN K IN PREVENTING OR COUNTERACTING COVID-19 DISEASE AND DIAGNOSTIC TEST TO ESTIMATE THE RISK OF DEVELOPING SEVERE DISEASE OR MORTALITY BY COVID-19 | EMPHYSEMA SOLUTIONS BV (NL) | 2023-07-27 | — | — | US | claimed |
| EP-3082865-B1 | PREVENTION AND COUNTERACTION OF DIET-INDUCED THROMBOSIS RISK | NATTOPHARMA ASA (NO) | 2021-08-11 | — | — | EP | claimed |
| US-20180199610-A1 | VITAMIN K AND CAPILLARY FUNCTION | VITAK BV (NL) | 2018-07-19 | — | — | US | claimed |
| US-20160310445-A1 | PREVENTION AND COUNTERACTION OF DIET-INDUCED THROMBOSIS RISK | VITAK B.V. (NL) | 2016-10-27 | — | — | US | claimed |
| EP-3082865-A1 | PREVENTION AND COUNTERACTION OF DIET-INDUCED THROMBOSIS RISK | VitaK B.V. (NL) | 2016-10-26 | — | — | EP | claimed |
| WO-2015092018-A1 | PREVENTION AND COUNTERACTION OF DIET-INDUCED THROMBOSIS RISK | VITAK BV (NL) | 2015-06-25 | — | — | WO | claimed |
| EP-2886129-A1 | Prevention and counteraction of diet-induced thrombosis risk | VitaK B.V. (NL) | 2015-06-24 | — | — | EP | claimed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | claimed |
| US-20130245598-A1 | PHOTOACTIVE VITAMIN NANOPARTICLES FOR THE TREATMENT OF CHRONIC WOUNDS | GOVERNORS STATE UNIVERSITY | 2013-09-19 | — | — | US | claimed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-20090074847-A1 | Transport System In Biological Systems | BIO TESYS GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| JP-2022241-A | — | — | None | — | — | JP | disclosed |
| WO-2024141616-A1 | HYDROLYSATE OBTAINED FROM INSECTS AND METHOD FOR PRODUCING SAID HYDROLYSATE | YNSECT (FR) | 2024-07-04 | — | — | WO | disclosed |
| CN-114451559-B | System and method for preparing powdery fat-soluble micronutrient premix and food | 北京金康普食品科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240189205-A1 | ENRICHED TOPICAL COSMETIC COMPOSITION | TruSkin Partners, Inc. (US) | 2024-06-13 | — | — | US | disclosed |
| EP-0816490-A2 | Mutant prenyl diphosphate synthase | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0747042-A1 | Compositions containing azole derivatives for topical application to skin | UNILEVER PLC (GB) | 1996-12-11 | — | — | EP | disclosed |
| CN-1106296-A | Nutritional Supplement | SANDOZ NUTRITION LTD (CH) | 1995-08-09 | — | — | CN | disclosed |
| JP-H0222241-A | FAT-SOLUBLE VITAMIN K-CONTAINING AQUEOUS SOLUTION | EISAI CO LTD | 1990-01-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310445-A1 | PREVENTION AND COUNTERACTION OF DIET-INDUCED THROMBOSIS RISK | PROC, F10, MAPK10 | LIPE 2211/4885HSD11B1 2453/4885MAOA 4617/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | LIPE 10/4885HSD11B1 189/4885MAOA 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.